首页> 美国卫生研究院文献>Patient preference and adherence >Orally disintegrating olanzapine review: effectiveness patient preference adherence and other properties
【2h】

Orally disintegrating olanzapine review: effectiveness patient preference adherence and other properties

机译:口服崩解性奥氮平评价:有效性患者喜好依从性和其他特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Orally disintegrating olanzapine (ODO) is a rapid-dissolving formulation of olanzapine which disintegrates in saliva almost immediately, developed as a convenient and adherence-enhancing alternative to the standard olanzapine-coated tablet (SOT). Clinical studies, which form the basis of this review, have shown ODO and SOT to have similar efficacy and tolerability profiles. However, ODO appears to have a number of advantages over SOT in terms of adherence, patient preference, and reduction in nursing burden. Overall, the existing clinical data suggests that compared to SOT, ODO is not only well-suited for difficult-to-treat, agitated, and/or nonadherent patients but, due to its potential ability to improve adherence and greater patient preference, may also be an appropriate formulation for the majority of patients for which olanzapine is the antipsychotic of choice.
机译:口服崩解性奥氮平(ODO)是奥氮平的一种快速溶解制剂,几乎可以立即在唾液中崩解,是作为标准的奥氮平包衣片(SOT)的方便且增强粘附力的替代品而开发的。构成本综述基础的临床研究表明,ODO和SOT具有相似的疗效和耐受性。但是,在依从性,患者偏爱和减轻护理负担方面,ODO似乎比SOT具有许多优势。总的来说,现有的临床数据表明,与SOT相比,ODO不仅非常适合难以治疗,情绪激动和/或不坚持的患者,而且由于其潜在的改善依从性和更大的患者偏爱的能力,还可能适用于奥氮平为首选抗精神病药的大多数患者的合适制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号